Loading…
NeuroSense Therapeutics Ltd.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in NRSN.
▲ +182.5% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $15.38 | $1.20 | $0.79 | $1.22 | |
| P/B | — | — | 10.8x | — | 2.6x |
| EPS | -$0.44 | -$0.54 | -$0.74 | -$0.91 | |
| ROE | — | — | -395.28% | — | -186.72% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ADVBAdvanced Biomed Inc. | $9.70 | 2.4x | 1.5x | — | 71.33% | $16.03M |
| AEONAEON Biopharma, Inc. | $0.31 | — | — | — | — | $15.67M |
| NMTCNEUROONE MEDICAL TECHNOLOGIES Corp | $1.77 | — | 4.1x | — | -124.66% | $16.12M |
| SCNXScienture Holdings, Inc. | $0.39 |
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Company description provided by Yahoo Finance.
| — |
| 0.3x |
| — |
| -53.47% |
| $16.18M |
| MDCXMedicus Pharma Ltd. | $0.26 | — | — | — | -7446.11% | $16.28M |
| HINDVyome Holdings, Inc | $2.21 | — | 2.6x | — | -999.17% | $15.48M |